Ixabepilone (Ixempra), a therapeutic option for locally advanced or metastatic breast cancer

P and T

Volumn 33, Issue 9, 2008, Pages 523-531

  Egerton, Nancy ^a  

^a Pharmacy Services   (United States)

Author keywords

Anthracyclines; Breast cancer; Capecitabine; Epothilones; Ixabepilone; Locally advanced; Metastatic; Taxanes

Indexed keywords

AMPRENAVIR; ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; BETA TUBULIN; CAPECITABINE; CREMOPHOR; CYTOCHROME P450 3A4; DELAVIRDINE; DOCETAXEL; EPOTHILONE B; EPOTHILONE DERIVATIVE; FLUCONAZOLE; INDINAVIR; ITRACONAZOLE; IXABEPILONE; IXABEPILONE C 14; IXEMPRA; KETOCONAZOLE; NELFINAVIR; PACLITAXEL; RADIOISOTOPE; RITONAVIR; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VERAPAMIL; VORICONAZOLE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADJUVANT THERAPY; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; APOPTOSIS; ARTHRALGIA; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG COST; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEAD AND NECK CARCINOMA; HEADACHE; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MONOTHERAPY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NAIL; NAUSEA; NEUROPATHIC PAIN; NEUTROPENIA; OVARY CANCER; PAIN; PERIPHERAL NEUROPATHY; PHARYNGITIS; PROSTATE CANCER; RASH; RECOMMENDED DRUG DOSE; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY EXCRETION; VOMITING;

EID: 53849116502     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period: A retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005;104:1742-1750.
3. Hamilton A, Hortobagyi G. Chemotherapy: What progress in the last 5 years? J Clin Oncol 2005;23:1760-1775.
4. Colozza M, de Azambuja E, Personeni N, et al. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist 2007;12:253-270.
5. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-1792.
6. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998;339:974-984.
7. Valero V, Hortobagyi GN. Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol 2003;21:959-962.
8. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 2004;9:617-632.
9. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005;205:275-292.
10. Lee JJ, Swain SM. Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol 2005;32(Suppl 7):S22-S26.
11. Clarke R, Leonessa F, Trock B. Multidrug resistance/P-glycoprotein and breast cancer: Review and meta-analysis. Semin Oncol 2005;32(Suppl 7):S9-S15.
12. Fornier M. Epothilones in breast cancer: Review of clinical experience. Ann Oncol 2007;18(Suppl 5):S16-S21.
13. Fojo AT, Menefee M. Microtubule targeting agents: Basic mechanisms of multidrug resistance (MDR). Semin Oncol 2005;32(Suppl 7):S3-S8.
14. Faneyte IF, Kristel PM, van de Vijver MJ. Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Res 2004;24:2931-2939.
15. Burger H, Foekens JA, Look MP, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: Correlation with chemotherapeutic response. Clin Cancer Res 2003;9:827-836.
16. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
17. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-799.
18. Ixempra (ixabepilone), package insert. Princeton, NJ: Bristol-Myers Squibb; October 2007.
19. Pivot X, Dufresne A, Villanueva C. Efficacy and safety of ixabepilone, a novel epothilone analogue. Clin Breast Cancer 2007;7:543-549.
20. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55:2325-2333.
21. Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: The epothilones. Oncologist 2007;12:271-280.
22. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on α,β-tubulin by electron crystallography. Science 2004;305:866-869.
23. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7:1429-1437.
24. Bode CJ, Gupta ML Jr, Reiff EA, et al. Epothilone and paclitaxel: Unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 2002;41:3870-3874.
25. Brooks TA, Minderman H, O'Loughlin KL, et al. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther 2003;2:1195-1205.
26. Rowinsky EK, Calvo E. Novel agents that target tublin and related elements. Semin Oncol 2006;33:421-435.
27. Goodin S, Kane MP, Rubin EH. Epothilones: Mechanism of action and biologic activity. J Clin Oncol 2004;22:2015-2025.
28. Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003;21:1866-1873.
29. Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004;10:1289-1298.
30. Spriggs DR, Soignet S, Bievenu B, et al. Phase 1 first-in-man study of epothilone B analog BMS-247550 in patients with advanced cancer (American Society of Clinical Oncology meeting, Abstract 428a). Proc Am Soc Clin Oncol 2001;20.
31. Gadgeel SM, Wozniak A, Boinpally RR, et al. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res 2005;11:6233-6239.
32. Zhuang SH, Agrawal M, Edgerly M, et al. A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 2005;103:1932-1938.
33. Awada A, Bleiberg H, de Valeriola D, et al. Phase I clinical and pharmacology study of the epothilone analog BMS-247550 given weekly in patients with advanced solid tumors (American Society of Clinical Oncology meeting, Abstract 427). Proc Am Soc Clin Oncol 2001;20.
34. Hao D, Hammond LA, deBono JS, et al. Continuous weekly administration of the epothilone-B derivative, BMS-247550 (NSC710428): A phase I and pharmacokinetic (PK) study (American Society of Clinical Oncology meeting, Abstract 411). Proc Am Soc Clin Oncol 2002;21.
35. Burris HA, Awada A, Jones S, et al. Phase I study of the novel epothilone BMS-247550 administered weekly in patients with advanced malignancies (American Society of Clinical Oncology meeting, Abstract 412). Proc Am Soc Clin Oncol 2002; 21.
36. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-3414.
37. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:3399-3406.
38. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005;23:2726-2734.
39. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:3415-3420.
40. Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007;25:3421-3427.
41. Baselga J, Gianni L, Llombart A, et al. Predicting response to ixabepilone: Genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (San Antonio Breast Cancer Symposium, Abstract 305). Breast Cancer Res Treat 2005;94(Suppl 1).
42. Denduluri N, Lee JJ, Walshe J, et al. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs 2007;25:63-67.
43. Lee FY, Camuso A, Castenada S, et al. Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts (American Society of Clinical Oncology meeting, Abstract 12017). J Clin Oncol 2006;24(Suppl 18S).
44. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-5217.
45. Vahdat L, Klimovsky J, Bunnell C. Phase I/II trial in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline: Final safety data (American Society of Clinical Oncology meeting, Abstract 1006). J Clin Oncol 2006;24(Suppl 18S).
46. Bunnell C, Klimovsky J, Thomas E. Final efficacy results of a phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline (American Society of Clinical Oncology meeting, Abstract 10511). J Clin Oncol 2006;24(Suppl 18S).
47. Vansteenkiste J, Lara PN Jr, Le Chevalier T, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007;25:3448-3455.
48. Burtness B, Goldwasser MA, Axelrod R, et al. A randomized phase II study of BMS-247550 (ixabepilone) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck (American Society of Clinical Oncology meeting, Abstract 5532). J Clin Oncol 2006;24(Suppl 18S).
49. Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110:556-563.
50. Liu G, Wang W, Dipaola R, et al. A phase II study of a weekly schedule of BMS-247550 for patients with hormone-refractory prostate cancer: A trial of the Eastern Cooperative Oncology Group (E3803) (American Society of Clinical Oncology meeting, Abstract 4618). J Clin Oncol 2007;24(Suppl 18S).
51. Hussain M, Tangen CM, Lara PN Jr, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: A Southwest Oncology Group trial S0111. J Clin Oncol 2005;23:8724-8729.
52. Dreicer R, Li S, Manola J, et al. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): A trial of the Eastern Cooperative Oncology Group. Cancer 2007;110:759-763.
53. Zhuang SH, Menefee M, Kotz H, et al. A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer (American Society of Clinical Oncology meeting, Abstract 4550). J Clin Oncol 2004;22(Suppl 14S).
54. Feldman DR, Kondagunta GV, Ginsberg MS, et al. Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Invest New Drugs 2007;25:487-490.
55. Whitehead RP, McCoy S, Rivkin SE, et al. A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone in patients with advanced pancreas cancer: A Southwest Oncology Group study. Invest New Drugs 2006;24:515-520.
56. Ajani JA, Safran H, Bokemeyer C, et al. A multicenter phase II study of BMS-247550 (ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs 2006;24:441-446.
57. Singh DA, Taber D, Ansari R, et al. A phase II trial of the epothilone B analog BMS-247550 in patients with hepatobiliary cancer (HBC): An updated analysis (American Society of Clinical Oncology meeting, Abstract 14050). J Clin Oncol 2006;24(Suppl 18S).
58. Smith SM, Pro B, van Besien K, et al. A phase II study of epothilone B analog BMS-247550 (NSC 710426) in patients with relapsed aggressive non-Hodgkin's lymphomas (American Society of Clinical Oncology meeting, Abstract 6625). J Clin Oncol 2005;23(Suppl 16S).
59. O'Connor O, Straus D, Moskowitz C, et al. Targeting the microtubule apparatus in indolent and mantle cell lymphoma with the novel epothilone analog BMS 247550 induces major and durable remissions in very drug resistant disease (American Society of Clinical Oncology meeting, Abstract 6569). J Clin Oncol 2005;23(Suppl 16S).
60. Aghajanian C, Burris HA III, Jones S, et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 2007;25:1082-1088.
61. Takimoto CH, Liu PY, Lenz H, et al. A phase I pharmacokinetic (PK) study of the epothilone B analogue, ixabepilone (BMS-247550), in patients with advanced malignancies and varying degrees of hepatic impairment: A Southwest Oncology Group Early Therapeutics Committee and NCI Organ Dysfunction Working Group trial (American Society of Clinical Oncology meeting, Abstract 2004). J Clin Oncol 2006;24(Suppl 18S).
62. Markman M. Management of toxicities associated with the administration of taxanes. Expert Opin Drug Saf 2003;2:141-146.
63. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601-609.
64. Goel S, Goldberg G, Iacono LC, et al. Effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone (American Society of Clinical Oncology meeting, Abstract 2005). J Clin Oncol 2006;24(Suppl 18S).
65. Gianni L. Ixabepilone and the narrow path to developing new cytotoxic drugs. J Clin Oncol 2007;25:3389-3391.
66. ClinicalTrials.gov: a service of the U.S. National Institutes of Health. Available at: www.clinicaltrials.gov. Accessed October 2007.
67. Academy of Managed Care Pharmacy (AMCP). Formulary Dossier for Ixempra (ixabepilone). November 2007.